Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	31.43B +4.0%
Revenue (ttm)	13.38B +1.8%
Net Income	2.25B -1.8%
EPS	2.52 +1.2%
Shares Out	n/a
PE Ratio	13.96
Forward PE	13.66
Dividend	1.20 (4.25%)
Ex-Dividend Date	Jun 13, 2025

Volume	368,240
Average Volume	1,012,284
Open	28.98
Previous Close	28.94
Day's Range	28.70 - 29.30
52-Week Range	25.60 - 41.85
Beta	0.38
RSI	55.93
Earnings Date	Mar 24, 2026

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neuro...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,878
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2025, HKG:1513's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.

Financial numbers in CNY